These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 28555422

  • 21. Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.
    Khasraw M, Holodny A, Goldlust SA, DeAngelis LM.
    Ann Oncol; 2012 Feb; 23(2):458-63. PubMed ID: 21543627
    [Abstract] [Full Text] [Related]

  • 22. Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis.
    Yang L, Chen CJ, Guo XL, Wu XC, Lv BJ, Wang HL, Guo Z, Zhao XY.
    J Neurooncol; 2018 Mar; 137(1):49-56. PubMed ID: 29170906
    [Abstract] [Full Text] [Related]

  • 23. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
    Narita Y.
    Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
    [Abstract] [Full Text] [Related]

  • 24. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients.
    Cachia D, Elshafeey NA, Kamiya-Matsuoka C, Hatami M, Alfaro-Munoz KD, Mandel JJ, Colen R, DeGroot JF.
    J Neurooncol; 2017 Oct; 135(1):75-81. PubMed ID: 28702781
    [Abstract] [Full Text] [Related]

  • 25. Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin.
    Bennett IE, Field KM, Hovens CM, Moffat BA, Rosenthal MA, Drummond K, Kaye AH, Morokoff AP.
    J Neurooncol; 2017 Jan; 131(2):321-329. PubMed ID: 27896520
    [Abstract] [Full Text] [Related]

  • 26. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
    Hilario A, Sepulveda JM, Hernandez-Lain A, Salvador E, Koren L, Manneh R, Ruano Y, Perez-Nuñez A, Lagares A, Ramos A.
    Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
    [Abstract] [Full Text] [Related]

  • 27. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.
    Yao J, Tan CHP, Schlossman J, Chakhoyan A, Raymond C, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM.
    J Neurooncol; 2019 May; 142(3):587-595. PubMed ID: 30806888
    [Abstract] [Full Text] [Related]

  • 28. Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy.
    Bronnimann C, Izquierdo C, Cartalat S, Thomas L, Joubert B, Delpech L, Barritault M, Meyronet D, Honnorat J, Ducray F.
    J Neurooncol; 2018 May; 138(1):141-145. PubMed ID: 29388033
    [Abstract] [Full Text] [Related]

  • 29. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH, Masalha W, Franco P, Machein MR, Weyerbrock A.
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: application of DSC perfusion MR imaging.
    Cho HR, Hong B, Kim H, Park CK, Park SH, Park S, Choi SH.
    Oncotarget; 2016 Oct 25; 7(43):69606-69615. PubMed ID: 27626306
    [Abstract] [Full Text] [Related]

  • 32. Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma.
    Bonekamp D, Mouridsen K, Radbruch A, Kurz FT, Eidel O, Wick A, Schlemmer HP, Wick W, Bendszus M, Østergaard L, Kickingereder P.
    J Cereb Blood Flow Metab; 2017 Feb 25; 37(2):485-494. PubMed ID: 26861817
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
    Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS.
    Expert Opin Pharmacother; 2011 Apr 25; 12(5):825-33. PubMed ID: 21385110
    [Abstract] [Full Text] [Related]

  • 35. Long-Term Prognostic Implications of Cerebral Microbleeds in Chinese Patients With Ischemic Stroke.
    Lau KK, Wong YK, Teo KC, Chang RSK, Tse MY, Hoi CP, Chan CY, Chan OL, Cheung RHK, Wong EKM, Kwan JSK, Hui ES, Mak HKF.
    J Am Heart Assoc; 2017 Dec 07; 6(12):. PubMed ID: 29217662
    [Abstract] [Full Text] [Related]

  • 36. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U, Sorensen M, Gaziel TB, Hasselbalch B, Poulsen HS.
    Anticancer Res; 2013 Apr 07; 33(4):1657-60. PubMed ID: 23564811
    [Abstract] [Full Text] [Related]

  • 37. Female sex, good performance status, and bevacizumab-induced hypertension associated with survival benefit in Asian patients with recurrent glioblastoma treated with bevacizumab.
    Liau CT, Chou WC, Wei KC, Chang CN, Toh CH, Jung SM.
    Asia Pac J Clin Oncol; 2018 Apr 07; 14(2):e8-e14. PubMed ID: 28792121
    [Abstract] [Full Text] [Related]

  • 38. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC, Kim BT.
    J Neurooncol; 2017 Jul 07; 133(3):561-569. PubMed ID: 28500559
    [Abstract] [Full Text] [Related]

  • 39. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH, Shen YL, Keegan P, Pazdur R.
    Oncologist; 2009 Nov 07; 14(11):1131-8. PubMed ID: 19897538
    [Abstract] [Full Text] [Related]

  • 40. Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.
    Tipping M, Eickhoff J, Ian Robins H.
    J Clin Neurosci; 2017 Oct 07; 44():101-106. PubMed ID: 28711289
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.